41
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Editor—Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. Although most patients have a favourable evolution, some patients have worse outcomes, progressing to acute respiratory distress syndrome (ARDS) and requiring treatment in an ICU.1, 2, 3, 4 Patients who survive may be susceptible to developing poor health-related quality of life (HRQoL) and persistent symptoms after ICU discharge; however, this has not been investigated. The present study aimed to determine the quality of life, functional status, and persistent symptoms of patients with COVID-19-induced ARDS at 6 months after requiring treatment in an ICU. The ethics committee of Galicia, Spain (code No. 2020-188), approved this study. Informed consent was obtained from all participants. We prospectively evaluated all critically ill patients with COVID-19-induced ARDS admitted to the ICUs of seven hospitals located in northwestern Spain between March 15 and April 30, 2020. A confirmed case of COVID-19 was defined by a positive result on a reverse-transcriptase polymerase chain reaction (RT–PCR) test. The following information was collected during ICU admission: patient characteristics, coexisting disorders, treatments, complications, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, laboratory tests, need for mechanical ventilation, tracheotomy, renal replacement therapy, duration of mechanical ventilation, length of ICU stay, and ICU outcomes. All patients who survived ICU admission were included to assess HRQoL, functional status, and persistent symptoms using a structured interview conducted by designated trained research coordinators at participating sites, 6 months after requiring ICU treatment. Patients were asked to recount their quality of life and functional status 3–6 months before COVID-19 at the time of the interview. HRQOoL was assessed using the EuroQol Group Association five-domain, three-level questionnaire (EQ-5D-3L), which consists of two sections: the descriptive system and the visual analogue scale. The descriptive system assesses five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with three possible responses options: no problems, some problems, or extreme problems. The individual domains were converted to a utility score (EQ-5D index), a continuous range from –0.59 to 1.00, with 1.00 indicating ‘full health’ and 0 representing death. The visual analogue scale (EQ-VAS) represents 0 = worst imaginable health and 100 = best imaginable health. 5 Functional status was assessed according to the recently described Post-COVID-19 Functional Status scale (PCFS). 6 Persistent symptoms potentially correlated with COVID-19 were also obtained. All analyses were performed using R (version 4.0.2; R Foundation for Statistical Computing, Vienna, Austria) and IBM SPSS (version 26; SPSS, Inc, Chicago, IL, USA). The quantitative variables are expressed as median (inter-quartile range [IQR]) or median (standard deviation [sd]) and categorical variables as number (%). During the study period, 120 critically ill COVID-19 ARDS patients were admitted to the ICUs. Among the 120 patients, 23 (19%) died during ICU admission, and 5 within the first 6 months after ICU discharge. Ninety-two patients were potentially eligible for the 6 month follow-up assessment. One patient declined to participate. Therefore, 91 patients were included. Supplementary Table S1 displays the patient characteristics and clinical course during ICU stay of the study population. Of the 91 survivors at 6 month interview, a decrease in the quality of life was observed among 61 (67%) patients. The proportions of patients with moderate to extreme problems in the five dimensions studied with the EQ-5D-3L were mobility (56%), usual activities (37%), self-care (13%), pain/discomfort (48%), and anxiety/depression (46%) (Table 1 ). Table 1 Quality of life and functional status of the study sample (n=91). Data are expressed as n (%) or mean (standard deviation). Quality of life was measured using the EuroQol, five-dimension, three-level questionnaire and the EQ-VAS (0–100). Functional status was measured using the Post-COVID-19 Functional Status scale. Means for continuous variables were compared using unpaired or paired t-tests when the data were normally distributed; otherwise, the Mann–Whitney U-test or Wilcoxon test was used. Proportions for categorical variables were compared using Pearson's χ2 test or McNemar's test as appropriate. All tests were two-sided with a significance level of P<0.05. EQ-VAS, EuroQol visual analogue scale; EQ-5D-3L, EuroQol Group Association five-domain, three-level questionnaire. Table 1 Before COVID-19 6 months after COVID-19 P value Quality of life (EQ-5D-3L) Characteristics Mobility No problems 85 (93.4) 40 (44.0) <0.001 Some problems 6 (6.6) 51 (56.0) Unable to walk 0 (0.0) 0 (0.0) Self-care No problems 91 (100.0) 79 (86.9) <0.001 Some problems 0 (0.0) 10 (11.0) Unable to wash or dress myself 0 (0.0) 2 (2.2) Usual activities No problems 90 (98.9) 57 (62.6) <0.001 Some problems 1 (1.1) 24 (26.4) Unable to perform 0 (0.0) 10 (11.0) Pain or discomfort No pain or discomfort 81 (89.0) 47 (51.6) <0.001 Some pain or discomfort 10 (11.0) 36 (39.6) Extreme pain or discomfort 0 (0.0) 8 (8.8) Anxiety or depression Not anxious or depressed 85 (93.4) 49 (53.8) <0.001 Moderately anxious or depressed 6 (6.6) 38 (41.8) Extremely anxious or depressed 0 (0.0) 4 (4.4) EQ-5D index 0.9655 (0.0958) 0.7054 (0.2514) <0.001 EQ-VAS (0–100) 87.58 (11.68) 66.36 (18.26) <0.001 Post-COVID-19 Functional Status scale Grade 0: No limitations in my everyday life. 77 (84.6) 28 (30.8) <0.001 1: Negligible limitations, (still have persistent symptoms). 13 (14.3) 22 (24.2) 2: Limitations in my everyday life, and occasionally need avoid or reduce usual activities. 1 (1.1) 20 (22.0) 3. Limitations in my everyday life, and I am not able to perform all usual activities. 0 (0.0) 16 (17.6) 4. Severe limitations. I am dependent on another person because of symptoms. 0 (0.0) 5 (5.5) At the 6 month interview, 57 (63%) patients reported decreased functional status. Thirty-five (38%) patients had lowered two grades in the PCFS, and 41 (45%) patients described persistent functional limitations (grades 2–4 in the PCFS) (Table 1). Advanced age, male sex, need for mechanical ventilation during ICU stay, duration of mechanical ventilation, length of ICU stay, and length of hospital stay were associated with a decreased quality of life, decreased functional status at 6 months after ICU admission, or both (Supplementary Table S1). Supplementary Table S2 shows persistent symptoms potentially correlated with COVID-19 observed in the 91 patients. At the 6 month evaluation, a high proportion of patients reported dyspnoea on exertion (57%), asthaenia (37%), myalgia (37%), and arthralgia (29%). Only 15 (16%) patients were completely free of persistent symptoms. To our knowledge, this study represents the first description of the long-term health-related outcomes in survivors of COVID-19-associated ARDS. We found that at 6 months after requiring ICU admission, a large proportion of them had worsened quality of life, diminution of the functional status, and persistent symptoms compared with their pre-COVID-19 status. These data are consistent with prior studies that report poor long-term outcomes in critically ill survivors of ARDS not caused by COVID-19 and ICU survivors from other causes.8, 9, 10, 11, 12, 13 The term ‘long covid’ is being used to describe illness in people who have either recovered from COVID-19 but are still reporting long-term effects of the infection or have had the usual symptoms far longer than would be expected. 14 Follow-up clinics after hospital discharge are needed to characterise the sequelae of these patients, and to determine which interventions in the ICU, in the hospital after ICU discharge, and later in the community may mitigate or treat these sequelae. Research priorities include a better understanding of the pathophysiology, an evaluation of ICU and hospital treatments given, and impact of rehabilitation programmes on long-term outcomes after critical COVID-19. Early rehabilitation 15 or ICU diaries to help reduce post-traumatic stress disorder 16 have been described to mitigate long-term sequalae. A limitation of the present study is that it included only critically ill patients admitted to ICUs of hospitals located in northwestern Spain. Thus, the results may not reflect the experience and results of critically ill COVID-19 survivors of other ICUs in other regions. Another limitation is that the pre-COVID-19 assessment was based on patient recall of their quality of life and functional status, and these could be biased. Regardless, these preliminary results are shared to inform long-term health-related outcomes of critically COVID-19 patients who needed ICU admission. These findings may be important for health service planning and for planning the ongoing support and treatment of survivors of COVID-19 ARDS.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: found

          Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

          There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

            In December 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) emerged in China and has spread globally, creating a pandemic. Information about the clinical characteristics of infected patients who require intensive care is limited.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              EuroQol--a new facility for the measurement of health-related quality of life.

              (1990)
              In the course of developing a standardised, non-disease-specific instrument for describing and valuing health states (based on the items in Table 1), the EuroQol Group (whose members are listed in the Appendix) conducted postal surveys in England, The Netherlands and Sweden which indicate a striking similarity in the relative valuations attached to 14 different health states. The data were collected using a visual analogue scale similar to a thermometer. The EuroQol instrument is intended to complement other quality-of-life measures and to facilitate the collection of a common data set for reference purposes. Others interested in participating in the extension of this work are invited to contact the EuroQol Group.
                Bookmark

                Author and article information

                Journal
                Br J Anaesth
                Br J Anaesth
                BJA: British Journal of Anaesthesia
                British Journal of Anaesthesia. Published by Elsevier Ltd.
                0007-0912
                1471-6771
                10 December 2020
                10 December 2020
                Affiliations
                [1 ]Department of Anesthesiology and Intensive Care Medicine, Clinical University Hospital of Santiago, Sanitary Research Institute of Santiago (IDIS), Santiago, Spain
                [2 ]Department of Anesthesiology and Intensive Care Medicine, Clinical University Hospital of Ferrol, Ferrol, Spain
                [3 ]Department of Anesthesiology and Intensive Care Medicine, Clinical University Hospital of A Coruña, Coruña, Spain
                [4 ]Department of Anesthesiology and Intensive Care Medicine, Clinical University Hospital of Vigo, Vigo, Spain
                [5 ]Department of Anesthesiology and Intensive Care Medicine, Hospital POVISA of Vigo, Vigo, Spain
                [6 ]Department of Anesthesiology and Intensive Care Medicine, Clinical University Hospital of Pontevedra, Pontevedra, Spain
                [7 ]Department of Anesthesiology and Intensive Care Medicine, Clinical University Hospital of Ourense, Ourense, Spain
                [8 ]Preventive Medicine and Public Health Unit, Department of Health Sciences, University of A Coruña-INIBIC, A Coruña, Spain
                Author notes
                []Corresponding author.
                Article
                S0007-0912(20)30991-0
                10.1016/j.bja.2020.12.007
                7833644
                33413976
                0078c1d5-d649-417b-9689-66a2a9e428fb
                © 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 20 November 2020
                : 3 December 2020
                Categories
                Correspondence

                Anesthesiology & Pain management
                acute respiratory distress syndrome,covid-19,functional status,intensive care unit,patient-reported outcome measures,quality of life

                Comments

                Comment on this article